Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • keltus1952 keltus1952 Dec 28, 2013 1:59 AM Flag

    Wouldn't it be funny if the FDA...

    If the FDA didn't wait until Jan. 15th to make a decision? All those waiting to get the rock bottom lowest price will be burned for waiting to save a few cents. Monday pre open......could happen.....you never know.

    Kel..........a holder

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think the second it starts to go up, then something is brewing, aka the big boys know. Happened with aria two weeks ago when the stock went up approximately 10% each day for 3 days in a row, without any news (us little people weren't privy to any news, big boys were). I'd be shocked if we received news from the FDA before seeing the stock move significantly either way.

    • Absolutely possible, as it will happen by 15th. Means not after.
      "Funny"? Well, that only with good news.

    • That's what happened with ARIA last week -- you never know what management is doing behind the scenes and this company is described as "pulling out all the stops" to get approval...and now the old CEO is gone.
      -- Plus this stock has benefit of the investor-citizen petition which is credited with helping get the postponement, this has that extra going for it.
      -- I HOPE the bottom feeders trying to take it back down to where it was before last week get SCALDED.
      -- There seems to be a sense of worry being left out b/c last night's close at $1.82 was "painted" by some devious Market Marker: end of Day had crept back up to 1.85 then suddenly BAM taken down to the low in
      the last few minutes.

      Sentiment: Strong Buy

      • 1 Reply to lu.madar87
      • Here's how Zachs sums it up:

        The FDA will now view Amarin's appeal of the ANCHOR SPA agreement rescission and the ANCHOR sNDA separately. Amarin's request to reinstate the ANCHOR SPA agreement will be reviewed by FDA before Jan 15, 2014.

        We note that Vascepa, the only marketed product of the company, is already approved in the U.S. as an adjunct to diet for reducing triglyceride levels in adults suffering from severe hypertriglyceridemia (triglyceride ≥ 500mg/dL). Amarin refers to this as the MARINE indication. Amarin started marketing the drug in the U.S. in Jan 2013 and. reported $8.4 million in sales of Vascepa in the third quarter of 2013.

        Amarin is leaving no stone unturned to successfully commercialize Vascepa (MARINE indication) and expand the drug’s label into the ANCHOR indication.

 
AMRN
3.070.00(0.00%)Aug 25 4:00 PMEDT